Analysis of Circulating Tumor Markers in the Blood

Trial Profile

Analysis of Circulating Tumor Markers in the Blood

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Palbociclib
  • Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Biomarker; Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 11 May 2017 New trial record
    • 29 Apr 2017 Results of circulating tumor DNA changes (n=15) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top